Thromboxane A2 (TXA2) is an effective constrictor of vascular smooth muscle and aggregator of platelets. These effects are mediated via membrane receptors that belong to the super family of G protein coupled receptors. The synthesis of TXA2, particularly by platelets, is increased in a variety of cardiovascular and renal diseases. Aspirin inhibits the platelet synthesis of TXA2 and because aspirin is effective in the treatment and prevention of acute coronary artery syndromes, it has been postulated that TXA2 plays an important pathophysiologic role in these syndromes. The long range objectives of this laboratory are to determine the relationship of structure to function for human platelet TXA2 receptors. To meet these objectives the PI has proposed the following specific aims: 1) determine the role of conserved histidines, serines and arginine-295 in ligand binding to the platelet TXA2 receptor, 2) determine the sites of attachment for affinity probes to TXA2 receptors and 3) synthesize affinity and photoaffinity probes that will be used to elucidate the relationship of structure to function for TXA2 receptors. These studies will use a combination of molecular biology to clone and mutate specific amino acids of the cloned, carboxy terminal hexahistidine tagged TXA2 receptors, rapid receptor purification techniques, cell culture, radioligand equilibrium and competition binding assays, pharmacologic and biochemical assays, and affinity labeling of TXA2 receptors coupled with proteolysis and sequencing using state of the art mass spectrometry. The results of these experiments will be used to begin to develop a computer generated model of the ligand binding domain of TXA2 receptors. These studies should provide a better fundamental understanding of the relationship of structure to function for this important class of receptors and may ultimately lead to the development of specific antagonists of TXA2 receptors for the treatment of a variety of cardiovascular and renal diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL036838-10
Application #
6030553
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1986-07-01
Project End
2002-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Pharmacology
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Qiao, Na; Reynaud, Denis; Demin, Peter et al. (2003) The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells. J Pharmacol Exp Ther 307:1142-7
Taylor, Dawne M; Halushka, Perry V; Meier, G Patrick (2003) Hydrogen bond interactions of a series of N-substituted TXA2 receptor antagonists. Eur J Med Chem 38:1015-24
Halushka, Marc K; Walker, Linda P; Halushka, Perry V (2003) Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73:122-30
Halushka, Marc K; Halushka, Perry V (2002) Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105:1620-2
Halushka, P V (2000) Thromboxane A(2) receptors: where have you gone? Prostaglandins Other Lipid Mediat 60:175-89
Becker, K P; Garnovskaya, M; Gettys, T et al. (1999) Coupling of thromboxane A2 receptor isoforms to Galpha13: effects on ligand binding and signalling. Biochim Biophys Acta 1450:288-96
Wang, G R; Zhu, Y; Halushka, P V et al. (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 95:4888-93
Pawate, S; Schey, K L; Meier, G P et al. (1998) Expression, characterization, and purification of C-terminally hexahistidine-tagged thromboxane A2 receptors. J Biol Chem 273:22753-60
Becker, K P; Ullian, M; Halushka, P V (1998) Cloning and characterization of an endogenous COS-7 cell thromboxane A2 receptor. Biochim Biophys Acta 1403:109-14
Brothers, T E; Robison, J G; Elliott, B M et al. (1997) Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg 5:92-8

Showing the most recent 10 out of 56 publications